Last reviewed · How we verify
Cilta-cel OOS Therapy
Chimeric antigen receptor T-cell therapy
Chimeric antigen receptor T-cell therapy Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | Cilta-cel OOS Therapy |
|---|---|
| Also known as | JNJ-68284528 |
| Sponsor | Janssen Scientific Affairs, LLC |
| Drug class | CAR-T cell therapy |
| Target | BCMA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Cilta-cel is a chimeric antigen receptor T-cell therapy that selectively targets and eliminates cancer cells.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
- A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |